Clinical trials: Complication of Infusion
Ovarian Neoplasms
Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)
The purpose of this study is to evaluate the safety and tolerability of Caelyx in women with advanced ovarian cancer, focusing on infusion reactions and palmar-plantar erythrodysesthesia.
- Trial name
- NCT00743431
- Testing
- Caelyx (Pegylated Lyposomal Doxorubicin)
- Volunteers
- 224 people
- Sponsor
- Merck Sharp & Dohme LLC
Laminectomy
Esmolol Infusion During Laminectomy: Effect on Quality of Recovery
The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain…
- Trial name
- NCT01179113
- Testing
- Esmolol, Saline
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Cedars-Sinai Medical Center
Diabetes
Nitrite Infusion in Islet Cell Transplantation
This study seeks to investigate the effects of administering nitrite to pancreatic islet cells that have been removed from a patient for autotransplantation.
- Trial name
- NCT03544242
- Testing
- Control, Pre-Isolation Infusion, Post-Isolation Infusion
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Alabama at Birmingham
Anemia, Pregnancy Complications
Intravenous Versus Oral Iron in Late Pregnancy: Results of Treatment
The purpose of this study is to compare the efficacy of body iron storage replenishment between low dose intravenous iron and oral iron in late pregnancy.
- Trial name
- EIVF (NCT00746551)
- Testing
- Ferli-6® (Continental Pharm co., ltd.), Venofer® (Vifor AG, St. Gallen, Switzerland)
- Where
- Thailand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Metastatic Cancer, Metastatic Melanoma
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients metastatic cancer that involves taking white blood cells from the patient, growing them in the laboratory…
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Renal Cancer
- Trial name
- NCT01218867
- Testing
- Anti-VEGFR2 CAR CD8 plus PBL, Cyclophosphamide, Aldesleukin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Fatigue, End Stage Renal Disease (ESRD)
Lipid Infusion in Dialysis Patients With Endotoxemia
The purpose of this study is to determine whether a phospholipid emulsion is effective in the treatment of chronic endotoxemia in hemodialysis patients.
- Trial name
- LIPIDOSE (NCT00506454)
- Testing
- Lipidose
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Sepsicure
Anti-p53 TCR-Gene
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
Background: The p53 gene normally suppresses tumor growth, but when it is mutated, or damaged, tumors can grow unchecked. In cancers where the p53 gene has mutated, an increased level of p53(overexpression of p53) can be measured…
- Trial name
- NCT00393029
- Testing
- anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes, aldesleukin, filgrastim
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Cardiorenal Syndrome
Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure
The objective of this study is to determine the safety and effectiveness of intrarenal administration of brain natriuretic peptide (BNP) in improving renal function as measured by glomerular filtration rate (GFR) and sodium…
- Trial name
- NCT00348556
- Testing
- Nesiritide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Horng Chen
COL6A3 Positive, HLA-A*0201 Positive Cells Present
T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
This phase I/Ib trial studies the side effects and best dose of utomilumab and how well it works with CD8-positive T-lymphocyte (T-cell infusion) and aldesleukin in treating patients with ovarian cancer that has come back.
- Conditions
- COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive, Recurrent Ovarian Carcinoma
- Trial name
- NCT03318900
- Testing
- Aldesleukin, CD8-Positive T-Lymphocyte, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer, Melanoma (Skin)
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
RATIONALE: Gene-modified lymphocytes may stimulate the immune system in different ways and stop tumor cells from growing. High-dose aldesleukin may stimulate lymphocytes to kill tumor cells.
- Conditions
- Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00704938
- Testing
- aldesleukin, anti-p53 T-cell receptor-transduced peripheral blood lymphocytes, autologous dendritic cell-adenovirus p53 vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Post-operative Pain, Respiratory Depression
Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients
The purpose of this study is to evaluate the safety, efficacy, hemodynamic and respiratory stability of a low-dose of dexmedetomidine infusion in post-operative surgical in-patients undergoing thoracic surgery after discharge…
- Trial name
- NCT00345384
- Testing
- Dexmedetomidine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Baylor Research Institute
Infusion Site Injury
Study to Estimate the Point Prevalence of Peripheral Intravenous Catheter-related Complications in Brazil
A multi-center, national prevalence study where: (1) baseline SPIVC therapy complications of hospitalized adult patients that meet the inclusion/exclusion criteria of the study and (2) the compliance of clinicians to the…
- Trial name
- PIVS (NCT03719287)
- Where
- 3 sites in Brazil
- Volunteers
- 295 people
- Sponsor
- Solventum US LLC
Surgical Site Infection
Continuous Antibiotic Prophylaxis in Colorectal Surgery
We propose to randomise patients due to undergo colorectal surgery to standard antibiotic prophylaxis or an interventional antibiotic prophylaxis regimen and assess surgical wound infection rates.
- Trial name
- Colo-Pro (NCT02445859)
- Testing
- Cefuroxime 4 hourly bolus
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Leeds
Renal Impairment
Pharmacokinetic Assessment of Sodium Sulfide in Subjects With Impaired Renal Function
This is a Phase 1 study to assess the pharmacokinetics (PK) of IK-1001 (sodium sulfide) in healthy volunteers as well as in subjects with varying degrees of impaired renal function.
- Trial name
- NCT00879645
- Testing
- Sodium Sulfide
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Mallinckrodt
End Stage Renal Disease, Chronic Kidney Diseases
Berinert (C1INH) vs Placebo for DGF/IRI
This is a Phase I/II double-blind, randomized, placebo-controlled study assessing safety and limited efficacy of intraoperative C1INH (500U/kidney) vs.
- Trial name
- NCT04696146
- Testing
- Berinert
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cedars-Sinai Medical Center
Metastatic Melanoma, Metastatic Renal Cell Cancer
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
Background: -This study uses an experimental cancer treatment that uses the patient s own lymphocytes (type of white blood cell), which are specially selected and genetically modified to target and destroy their tumor.
- Conditions
- Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer
- Trial name
- NCT00670748
- Testing
- Anti-NY ESO-1 T-cell receptor PBL, aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Cancer Institute (NCI)